[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypothyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypothyroidism":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,41,68,97,131,154,175,201,239,264,289,314,339,368,390,417,440,472,495,517],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":4,"leadSponsor":37,"locationsCount":40},"100054236","natural-history-of-thyroid-function-disorders-100054236",false,"NCT00001159","Natural History of Thyroid Function Disorders","* INCLUSION CRITERIA:\n\nThe categories of subjects eligible to participate in this study include:\n\n1. Patients with known or suspected thyroid abnormalities (e.g. hypothyroidism, hyperthyroidism, extreme iodine deficiency, and inherited forms of hypothyroidism resulting from abnormalities in the expression of genes coding for the TSH- beta subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS.\n2. Patients with thyroid function test (TFT) abnormalities due to:\n\n   * Non-thyroidal illness\n   * Abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia or hypotriiodothyronemia.\n   * Genetic deficiency of thyroxine-binding globulin (TBG).\n   * Antibodies to mouse immunoglobulins leading to an artifactual elevation in the TSH ultrasensitive (\"3rd generation\") assay which may mimic \"inappropriate\" secretion of TSH.\n\nInclusion and exclusion criteria for each group of subjects are given below.\n\nPatients with known or suspected thyroid abnormalities will be eligible to p rticipate if the individual meets all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 6 months+.\n\nHyperthyroid states include but are not restricted to:\n\n1. Graves' disease (GD) thought to result from thyroid-stimulating immunoglobulins (TSIg's), a subclass of which also stimulate eye muscle and fatty tissue producing exophthalmos (Graves' ophthalmopathy), as well as the skin in the pretibial area causing pretibial myxedema (Graves' dermopathy);\n2. Subacute thyroiditis (SAT), a painful inflammation thought to result from viral infection with Coxsackie, as well as other viruses;\n3. Silent thyroiditis, a painless inflammation thought to result from autoimmune attack of thyrocytes by antimicrosomal antibodies directed against thyroid peroxidase (TPO), as well as antithyroglobulin(anti-Tg) antibodies;\n4. Single or multiple hyperfunctioning thyroid nodules of unknown etiology, probably resulting from the activation of certain thyroid oncogenes and\u002For growth factors, such as the thyrotropin (TSH) receptor (TSHR) and the a-subunit of the G protein (Ga);\n5. Iodide-induced hyperthyroidism of unknown etiology;\n6. Surreptitious administration of thyroid hormone (TH), usually present in patients with underlying psychiatric disease or occasionally related to patients with obesity and other eating disorders\n7. Trophoblastic neoplasms, thought to result from high levels of hCG secretion, which, because of its structural similarity to TSH, causes \"spillover\" of action at the TSHR level;\n8. \"Inappropriate\" secretion of TSH, which may be present either in patients with TSH- producing pituitary tumors (TSHomas) or from a non-neoplastic cause, i.e. pituitary resistance to the action of thyroid hormone (3,4).\n\nHypothyroid states include but are not restricted to:\n\n1. Primary (or thyroidal) hypothyroidism, usually resulting from auto-antibodies to thyroid proteins, such as antimicrosomal antibodies to TPO usually associated with lymphocytic (Hashimoto's) thyroiditis (HT) or atrophic thyroiditis, or blocking antibodies to the TSHR, usually in the context of non-goitrous hypothyroidism;\n2. Secondary (or pituitary) hypothyroidism, usually resulting from tumors of the pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or prolactinomas;\n3. Tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology or secondary to a pituitary tumor;\n4. Bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic hormones or secondary to pituitary tumors (and usually related to abnormal glycosylation patterns of the TSH molecule);\n5. Generalized resistance to thyroid hormone (RTH), a disease which has been shown to be due to abnormalities in the TH receptor, c-erbA-beta (or TR- beta).\n\nThe above are the principal disorders under study, but we may also investigate other abnormalities, such as extreme iodine deficiency, and inherited forms of hypothyroidism resulting from abnormalities in the expression of genes coding for the TSH- beta subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS (among others).\n\nEXCLUSION CRITERIA:\n\nThere are no exclusion criteria for subjects with known or suspected thyroid abnormalities.","ALL","6 Months","98 Years",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves' Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas.\n\nThe main purpose of this study is to further understand the natural history, clinical presentation, and genetics of thyroid function disorders. Many of the tests performed are in the context of standard medical care that is offered to all patients with thyroid function disorders. In addition, blood and tissue samples may be taken for research and genetic studies.",[24,25,26],"Hyperthyroidism","Hypothyroidism","Grave's Disease",[24,25,26,28,29],"Natural History","Thyroid-Stimulating Hormone Secreting Pituitary Ad","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":34},"1977-02-01",{"name":38,"class":39},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100650325","phase-3-an-open-label-single-arm-study-to-investigate-the-efficacy-and-safety-of-north-star-desiccated-porcine-thyroid-extract-tablets-100650325","NCT07747103","An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.","An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets for the Treatment of Primary Hypothyroidism","Inclusion Criteria:\n\n* Diagnosed with primary hypothyroidism, including Hashimoto's Thyroiditis, and on therapy with a stable dose of LT4 (minimum 50 mcg per day, administered 7 days per week) for at least 12 weeks prior to Screening\n* Have had euthyroid status for at least 6 weeks and up to 12 months prior to Screening (Visit 1), with at least one documented minimum stable dose of 50 mcg LT4.\n* Agree to practice a method of contraception\n* Female patients not pregnant or lactating at Screening\n* Agree to practice a method of contraception of greater than 90% reliability\n* Willing to give written informed consent for the Study\n* Provide written authorization for use and disclosure of protected health information\n\nExclusion Criteria:\n\n* Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation or excretion of North Star\n* Hospitalization for a major illness within 5 weeks prior to Screening\n* Concomitant use of prohibited medications or supplements\n* Have uncontrolled diabetes\n* Taking or having taken prescription or over-the-counter weight loss medications within 6 weeks prior to Screening\n* Participated in another investigational new drug study within 30 days or 5 half-lives of the IMP, whichever is longer, prior to the first study drug administration.\n* For female subjects, be pregnant, nursing or planning to become pregnant during the study","18 Years","75 Years",{"count":51,"type":20},466,"INTERVENTIONAL",[54],"PHASE3","The North Star study is a multi-center, Phase 3, open-label, single-arm clinical study to evaluate the Efficacy and Safety of North Star therapy.",[25],"2026-07-30",{"date":59,"type":34},"2026-08-05",{"date":61,"type":34},"2026-06-30",{"date":63,"type":20},"2027-12",{"name":65,"class":66},"Neuvosyn Laboratories, LLC","INDUSTRY",25,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100649300","evaluation-of-levothyroxine-replacement-therapy-after-total-thyroidectomy-using-a-smart-wristband-100649300","NCT07733375","Evaluation of Levothyroxine Replacement Therapy After Total Thyroidectomy Using a Smart Wristband","Comparative Evaluation of the Effectiveness of Levothyroxine Replacement Therapy After Total Thyroidectomy Using Smart Wristband-Measured Nocturnal Heart Rate and Heart Rhythm Parameters Versus Thyroid Function Tests","SMART-THY","Inclusion Criteria:\n\nAge 18 years or older. Undergoing total thyroidectomy at the Department of General Surgery, Yeditepe University Faculty of Medicine Hospital.\n\nInitiation of levothyroxine as part of routine postoperative clinical care. Willing and able to attend the routine 1-month postoperative thyroid function test follow-up visit.\n\nWilling and able to wear the Xiaomi Smart Band 10 throughout the study period. Able to provide written informed consent.\n\nExclusion Criteria:\n\nHistory of cardiac arrhythmia. Current use of beta-blockers or other antiarrhythmic medications that may affect heart rate.\n\nHistory of heart failure or advanced cardiovascular disease. Diagnosed sleep disorders that may interfere with nighttime heart rate measurements.\n\nPregnancy. Inability or unwillingness to wear the smart wristband as required. Missing clinical or laboratory data required for outcome assessment. Refusal to participate or withdrawal of informed consent.",{"count":77,"type":20},40,"The goal of this observational study is to determine whether nighttime heart rate and heart rhythm data collected by a smart wristband can identify under- or over-replacement with levothyroxine before the routine 1-month thyroid function tests in adults who have undergone total thyroidectomy.\n\nAfter total thyroidectomy, patients usually start levothyroxine replacement therapy, and the dose is adjusted about 1 month later based on thyroid function tests. This study aims to determine whether changes in nighttime heart rate and heart rhythm can provide an earlier indication that the levothyroxine dose is too low or too high.\n\nThe main questions it aims to answer are:\n\nCan nighttime heart rate and heart rhythm measured by a smart wristband identify under- or over-replacement with levothyroxine before routine thyroid function testing? How well do smart wristband measurements agree with thyroid function test results?\n\nParticipants will:\n\nWear a smart wristband after total thyroidectomy. Continue taking levothyroxine as prescribed by their physician. Undergo routine thyroid function testing approximately 1 month after surgery as part of standard clinical care.\n\nAllow researchers to compare smart wristband measurements with thyroid function test results to evaluate whether wearable data can provide an earlier indication of inadequate or excessive levothyroxine replacement.",[80,24,25],"Total Thyroidectomy",[80,82,83,84,85,86],"Levothyroxine Replacement Therapy","Wearable Devices","Nighttime Heart Rate","Postoperative Hypothyroidism","Postoperative Hyperthyroidism","2026-07-24",{"date":89,"type":34},"2026-07-29",{"date":91,"type":34},"2026-07-22",{"date":93,"type":20},"2027-02-01",{"name":95,"class":96},"Yeditepe University Hospital","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":40},"100647448","internal-organ-and-musculoskeletal-assessment-in-hypothyroidism-hypomorph-100647448","NCT07707830","Internal Organ and Musculoskeletal Assessment in Hypothyroidism (HYPOMORPH)","Morphometric Characteristics of Internal Organs and Morphofunctional Status of the Musculoskeletal System in Patients With Hypothyroidism","HYPOMORPH","Inclusion Criteria:\n\n* Adults aged 18-59 years.\n* Previously established diagnosis of hypothyroidism.\n* Receiving routine outpatient or inpatient care at participating healthcare institutions.\n* Ability to undergo ultrasonographic, anthropometric, and functional assessments.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* History of thyroid malignancy.\n* Acute infectious or inflammatory disease at the time of enrollment.\n* Severe decompensated cardiovascular, hepatic, or renal disease preventing study procedures.\n* Neurological or musculoskeletal disorders that preclude functional testing.\n* Refusal or inability to provide informed consent.\n* Incomplete clinical or laboratory data.",{"count":106,"type":20},500,"This hospital-based observational cross-sectional study aims to investigate the morphometric characteristics of internal organs and the morphofunctional status of the musculoskeletal system in adult patients with previously diagnosed hypothyroidism. The study will evaluate ultrasonographic morphometric characteristics of the liver, pancreas, and kidneys, as well as anthropometric and functional characteristics of the musculoskeletal system. Associations between these outcomes and clinical characteristics, anthropometric parameters, physical activity, and laboratory findings will also be assessed. The study is expected to identify accessible clinical, anthropometric, and functional markers associated with morphometric and musculoskeletal changes in patients with hypothyroidism, thereby improving risk assessment and early detection of systemic involvement.",[25],[25,110,111,112,113,114,115,116,117,118,119,120],"Ultrasonography","Morphometry","Liver","Pancreas","Kidney","Musculoskeletal System","Anthropometry","Physical Function","Cross-Sectional Study","Physical Activity","Physical Inactivity","NOT_YET_RECRUITING","2026-07-14",{"date":124,"type":34},"2026-07-16",{"date":126,"type":20},"2026-08-01",{"date":128,"type":20},"2028-12-31",{"name":130,"class":96},"Andijan State Medical Institute",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":52,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":40},"100643222","effect-of-medication-adherence-based-digital-intervention-on-fatigue-severity-weight-and-thyroid-hormone-regulation-100643222","NCT07636681","Effect of Medication Adherence-Based Digital Intervention on Fatigue Severity, Weight, and Thyroid Hormone Regulation","Effect of Medication Adherence-Based Digital Intervention on Fatigue Severity, Weight, and Thyroid Hormone Regulation in Patients With Hypothyroidism: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults (≥18 years) with primary hypothyroidism.\n* On stable levothyroxine therapy for at least 3 months.\n* Able to read, understand study instructions\n* capable of using basic mobile applications\n* poor medication adherence, clinically significant fatigue, documented weight fluctuations and abnormal thyroid hormone\n\nExclusion Criteria:\n\n* Secondary hypothyroidism or recent thyroidectomy\u002Fradioactive iodine therapy.\n* Pregnancy or breastfeeding woman.\n* Severe psychiatric disorders or cognitive impairment\n* significant visual or hearing deficits\n* Serious comorbidities affecting medication adherence (e.g., chronic disease, renal, or hepatic disease).\n* take dietary supplements or medications that interfere with levothyroxine absorption.","60 Years",{"count":140,"type":20},80,[142],"NA","1. To evaluate the effect of a medication adherence-based digital intervention on fatigue severity in patients with hypothyroidism.\n2. To assess the effect of a medication adherence-based digital intervention on weight in patients with hypothyroidism.\n3. To investigate the effect of a medication adherence-based digital intervention on thyroid hormone regulation in patients with hypothyroidism.",[25],"2026-06-03",{"date":147,"type":34},"2026-06-09",{"date":149,"type":20},"2026-06-01",{"date":151,"type":20},"2026-12-30",{"name":153,"class":96},"University of Baghdad",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":52,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100572322","phase-2-novel-approaches-to-the-treatment-of-hypothyroidism-100572322","NCT06731764","Novel Approaches to the Treatment of Hypothyroidism","Inclusion Criteria:\n\nHistory of hypothyroidism Treatment with levothyroxine Levothyroxine dose \\>1.2 mcg\u002Fkg\n\nExclusion Criteria:\n\nBody weight \\\u003C50 or \\>100 Kg.\n\nIndication for TSH suppression (high risk follicular-derived thyroid cancer).\n\nSecondary (pituitary) hypothyroidism (ICD-10 E23.0); Pregnancy; breastfeeding; uncontrolled diabetes (HbA1c \\>8.5% at screening); use of oral Semaglutide (Rybelsus); Uncontrolled Hypertension (BP \\> 140\u002F90 at screening); current use of T3-containing therapies (Liothyronine, desiccated thyroid extracts).\n\nPatients receiving lipid-lowering therapies must maintain the same dose throughout the participation in the study. Changes in lipid lowering therapy\u002Fdose will result in termination from the study.\n\nPatients receiving anti-acid (H2 blockers, proton pump inhibitors) therapies must maintain the same dose throughout the participation in the study. Changes in anti-acid therapy\u002Fdose will result in termination from the study. Use of other medications known to interfere with the absorption of thyroid hormone, or affecting the thyroid hormone axis (Burch 2019) will be considered exclusion criteria.\n\nBariatric surgery, initiation of GLP-1 agonist therapy (irrespective of the indication), enrollment in structured weight loss programs will result in dismissal from the study.\n\nCurrent pregnancy, pregnancy planned within the next 6 months, and lack of contraception in women of reproductive age will be exclusionary. We will verify that the participant is not pregnant through a urine pregnancy test at the time of the first study visit and at each of the follow-up visits. Any participants who become pregnant will terminate the study.",{"count":161,"type":20},90,[163,54],"PHASE2","Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine.\n\nThere is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine\u002Fliothyronine combination therapy in patients living with hypothyroidism.\n\nTo address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine\u002Fliothyronine combination therapy.",[25],"2026-03-17",{"date":168,"type":34},"2026-03-19",{"date":170,"type":34},"2024-12-10",{"date":172,"type":20},"2028-06-30",{"name":174,"class":96},"UConn Health",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":15,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":52,"phases":186,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100521751","phase-4-dosing-of-lt4-in-older-individuals-100521751","NCT06073665","Dosing of LT4 in Older Individuals","Levothyroxine Dosing in Older Individuals","DOT4","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, community dwelling, aged 65 years or older\n4. Diagnosed with hypothyroidism of any etiology for at least 6 months, taking 75-200 mcg per day LT4 and a minimum of 1.2 mcg\u002Fkg\u002Fday with no dose adjustment since the last TSH test.\n5. Ability to take oral medication and be willing to adhere to the medication regimen\n6. Adherence to lifestyle considerations.\n\nExclusion Criteria:\n\n1. Hypopituitarism\n2. History of thyroid cancer requiring suppression of TSH secretion\n3. Current use of liothyronine (LT3), thyroid extracts, Tirosint liquid or capsules, and medications that interfere with thyroid function or thyroid function tests\n4. GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2 within the prior 12 months\n5. Unable to understand and comply with study requirements, as assessed by study staff and the PI, will be excluded.\n6. Other conditions which, in the opinion of the investigators, would prevent them from participating in the full duration of the study.\n7. Currently taking multikinase or checkpoint inhibitor therapy.\n8. Any history of food dye allergy.","65 Years",{"count":185,"type":20},228,[187],"PHASE4","Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.",[25],[191],"Levothyroxine Dosing","2026-02-17",{"date":194,"type":34},"2026-02-19",{"date":196,"type":34},"2024-01-31",{"date":198,"type":20},"2028-04-01",{"name":200,"class":96},"University of Pennsylvania",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":183,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":211,"conditions":212,"keywords":220,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":40},"100517290","comorbidities-resolution-after-mgb-surgery-and-change-in-body-composition-100517290","NCT06015620","Comorbidities Resolution After MGB Surgery and Change in Body Composition","CoMOrbidities Resolution After Mini-GAstric Bypass Surgery for Morbid Obesity and Change in BOdy Composition: A Prospective Cohort Study (MOGAMBO Study)","MOGAMBO","Inclusion Criteria:\n\n* All patients undergoing laparoscopic MGB surgery for morbid obesity and it's associated comorbidities\n\nExclusion Criteria:\n\n* Patients not giving consent for the study\n* All patients who were undergoing a redo-procedure for recurrence were excluded from the study",{"count":210,"type":20},35,"This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are:\n\nTo study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition.\n\nOther objectives are:\n\n* Changes in the parameters of the metabolic syndrome after surgery\n* Changes in the cardiovascular risk biomarkers after metabolic surgery\n* Emergence in complications arising out of surgery requiring any intervention or causing a prolonged hospital stay, or requiring additional outpatient visits.\n\nType of Study: An observational study in which participants with morbid obesity will undergo mini-gastric bypass surgery as per routine protocol. No separate experimental interventions will be done in the study for the participants.",[213,214,215,25,216,217,218,219],"Morbid Obesity","Type2diabetes","Sleep Apnea","Hypertension","Lipid Disorder","Non-Alcoholic Fatty Liver Disease","Chronic Venous Hypertension With Ulcer",[221,222,223,224,225,226,227,228,229],"morbid obesity","OSA","mini gastric bypass","metabolic surgery","polysomnography","metabolic syndrome","DEXA scan","bioelectrical impedance","body composition","2026-02-16",{"date":232,"type":34},"2026-02-18",{"date":234,"type":34},"2023-09-01",{"date":236,"type":20},"2027-03-30",{"name":238,"class":96},"All India Institute of Medical Sciences, Bhubaneswar",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":15,"minAge":246,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":52,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":40},"100625379","snuh-immune-checkpoint-inhibitor-induced-hypothyroidism-recovery-trial-100625379","NCT07421869","SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial","S-CORT","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Patients with a history of treatment with immune checkpoint inhibitors (ICIs).\n* Developed hypothyroidism during ICI treatment and initiated levothyroxine after starting ICI therapy.\n* Discontinued ICI therapy prior to study enrollment.\n\nExclusion Criteria:\n\n* Use of levothyroxine or antithyroid medications within 3 months prior to initiating ICI therapy.\n* History of thyroid surgery, radioactive iodine therapy, or neck radiation therapy.\n* Current levothyroxine dose ≥0.1 mg at the time of enrollment.","19 Years",{"count":248,"type":20},107,[142],"The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement.\n\nThe main questions the study will answer are:\n\n* What percentage of patients recover normal thyroid function and can stop levothyroxine after stopping ICIs?\n* What clinical or laboratory factors can predict successful withdrawal of levothyroxine?\n\nParticipants will:\n\n* Be adult cancer patients who developed hypothyroidism during ICI treatment and are currently taking levothyroxine\n* Have already stopped ICI therapy\n* Gradually reduce their levothyroxine dose every 3 months if their thyroid function remains normal\n* Stop levothyroxine if thyroid function remains normal at low doses (≤0.025 mg)\n* Be monitored with thyroid function tests and clinical symptoms at each visit",[25],[25,253,254,255],"Immune checkpoint inhibitors","Thyroid hormones","Levothyroxine","2026-02-11",{"date":194,"type":34},{"date":259,"type":34},"2024-06-12",{"date":261,"type":20},"2029-03-04",{"name":263,"class":96},"Seoul National University Bundang Hospital",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":15,"minAge":183,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":52,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100564445","optimizing-care-for-older-adults-through-thyroid-hormone-deprescribing-100564445","NCT06629272","Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing","Patient Eligibility:\n\nInclusion Criteria:\n\n1. age 65 years and older\n2. on thyroid hormone therapy and have a serum Thyroid-stimulating hormone (TSH) \\\u003C0.5 mIU\u002FL or are on thyroid hormone therapy for an inappropriate indication\n3. English speaking\n4. without cognitive impairment\n\nExclusion Criteria:\n\n1\\) Patients with a diagnosis of thyroid cancer, secondary hypothyroidism, history of total thyroidectomy or hospitalization in the past 3 months will be excluded.\n\nProvider eligibility:\n\nInclusion: Primary care physicians, endocrinologists, geriatricians, and Advanced Practice Providers (APPs) who practice at University of Michigan, Henry Ford Health System or University of California San Fransico (UCSF) and who prescribe thyroid hormone for eligible patients identified above will be eligible for study participation.\n\nExclusion: Providers who don't prescribe thyroid hormone.",{"count":271,"type":20},900,[142],"The proposed study focuses on testing a novel adapted evidence-based multilevel intervention, Deprescribing Thyroid Hormone In Older Adults (D-THIO), to support thyroid hormone deprescribing (dose de-escalation and\u002For discontinuation) in older adults with thyroid hormone overtreatment and\u002For misuse and reduce patient harm. Findings from this study will lay the groundwork for broad implementation of D-THIO and serve as a model for deprescribing inappropriate medications for other endocrine conditions and conditions with biochemical monitoring.",[25],[276,277,278],"thyroid hormone overtreatment and misuse","older adults","deprescribing","2026-02-10",{"date":281,"type":34},"2026-02-13",{"date":283,"type":34},"2024-12-02",{"date":285,"type":20},"2029-04",{"name":287,"class":96},"University of Michigan",3,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":296,"targetDuration":4,"studyType":52,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":313},"100542628","phase-2-a-study-to-assess-the-safety-and-efficacy-of-oral-armour-thyroid-compared-to-synthetic-t4-for-the-treatment-of-primary-hypothyroidism-in-adult-participants-100542628","NCT06345339","A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants","A Phase 2\u002F3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism","Inclusion Criteria:\n\n* Have a diagnosis of primary hypothyroidism made \\>= 12 months prior to Screening.\n* Be on continuous thyroid replacement therapy of synthetic T4 for primary hypothyroidism for at least 12 months immediately prior to the Screening Visit.\n* Be on a stable FDA-approved daily dose of synthetic T4 prior to the Screening visit, and must be taking synthetic T4 dose of at least 25 mcg at Screening visit. Must enter the study using the same stable dose to determine dose conversion.\n* Documentation of 1 in-range thyroid-stimulating hormone (TSH) (i.e., within 0.45 - 4.12 mIU\u002FL, inclusive) at Screening and at least 1 additional in range TSH (i.e., within 0.45 - 4.12 mIU\u002FL, inclusive) taken at a minimum of 6 weeks and a maximum of 12 months prior to Screening.\n\nExclusion Criteria:\n\n* Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion of Armour Thyroid or synthetic T4.\n* History of alcohol or other substance abuse within the previous 6 months prior to the Screening.\n* Known or suspected allergy or intolerance to any ingredients of Armour Thyroid, including its excipients, synthetic T4, other thyroid replacement medications, or pork products.",{"count":297,"type":20},2800,[163,54],"This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \\[TSH\\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.",[25],[25,302,303],"Armour Thyroid","Synthetic T4","2025-12-31",{"date":306,"type":34},"2026-01-05",{"date":308,"type":34},"2024-04-26",{"date":310,"type":20},"2028-06",{"name":312,"class":66},"AbbVie",139,{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":321,"sex":15,"minAge":48,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":40},"100522516","improvement-of-laboratory-diagnostics-in-hypothyroid-patients-using-levothyroxine-100522516","NCT06083636","Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine","ANTICIPATE","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a hypothyroid subject must meet all of the following criteria:\n\n* Ability to provide informed consent\n* Ability to speak and understand Dutch or English\n* Intake of a stable dosage of levothyroxine, meaning the dosage of levothyroxine must not be changed during the appointment at the outpatient clinic\n* Diagnosis of one these forms of hypothyroidism\n\n  * Patients with primary hypothyroidism: euthyroid based on TSH according to physician\n  * Patients with hypothyroidism after a total thyroidectomy due to thyroid carcinoma (therefore athyroid): on target TSH according to physician (target TSH depending on stage\u002Fseverity of carcinoma)\n  * Patients using L-T4 due to therapy of Graves' disease: euthyroid based on TSH according to physician (TSH cannot be suppressed, namely TSH within reference interval of 0,5-5,0 mU\u002FL)\n  * Patients with central hypothyroidism: euthyroid based on fT4 according to physician (common is fT4 in the upper limit, reference interval is 12-22 pmol\u002FL)\n\nIn order to be eligible to participate in this study, a healthy control subject must meet all of the following criteria:\n\n* Ability to provide informed consent;\n* Ability to speak and understand Dutch or English\n* Consider themselves healthy\n\nExclusion Criteria:\n\nA potential hypothyroid subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Not euthyroid according to physician\n* Pregnancy\n* Patients using L-T4 due to therapy of Graves' disease: if TSH is still suppressed\n* Any of the following medication\n\n  * Liothyronine (Cytomel)\n  * Iodide\n  * Oral contraceptives\n  * Active treatment of malignancy (other than thyroid carcinoma)\n\nA potential healthy control subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy\n* Any of the following medication\n\n  * Thyroid medication (a.o. levothyroxine, thiamazol, PTU)\n  * Lithium\n  * Amiodarone\n  * Propranolol\n  * Iodide\n  * Glucocorticoids\n  * Oral contraceptives\n  * Heparin\n  * Growth hormone\n  * Active treatment of malignancy",true,"100 Years",{"count":106,"type":20},"Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidism are treated with levothyroxine (L-T4) to supplement the lack of thyroxine (T4) produced by their own thyroid. Serum thyroid-stimulating hormone (TSH) and\u002For free T4 (fT4) are currently measured to assess the efficacy of this therapy and to establish euthyroidism. It is known that fT4 concentrations in patients using L-T4 can be above the upper limit of the reference interval, while their TSH is not (completely) suppressed. This raises the question whether fT4 is an accurate reflection of thyroid hormone status in patients using L-T4. TSH is considered a reliable parameter of thyroid hormone status; however, TSH cannot be used to assess thyroid function in specific hypothyroid patient groups (e.g. central hypothyroidism). Free triiodothyronine (fT3), the active thyroid hormone, has been suggested to be an interesting alternative of fT4 to assess thyroid function. Previously, the methods to measure fT3 were not that robust; however, methods to determine fT3 have been improved, are currently reliable and not susceptible to changes due to L-T4 intake. In addition, the fT3\u002FfT4 ratio is thought to be an interesting candidate in assessing thyroid hormone status as well. The aim of this study is to improve laboratory diagnostics of thyroid hormone status in patients with hypothyroidism receiving L-T4 in whom TSH cannot be used as a reflection of thyroid hormone status. We will primarily investigate the additional already available laboratory tests fT3 and fT3\u002FfT4 ratio. We hypothesize that treated hypothyroid participants who are assumed euthyroid based on TSH (e.g. patients with Hashimoto's hypothyroidism) but have fT4 concentrations above the upper reference limit will more often have a fT3 level or a fT3\u002FfT4 ratio within the reference interval. Concentrations of alternative markers in healthy controls and patients with Hashimoto's hypothyroidism with 'normal' TSH concentrations can, thus, be used to predict thyroid hormone status in patients using L-T4 in whom TSH cannot be used to assess thyroid hormone status.",[25],[25,255,327,328,329],"Laboratory diagnostics","Free triiodothyronine","Central hypothyroidism","2025-10-01",{"date":332,"type":34},"2025-10-03",{"date":334,"type":34},"2022-07-26",{"date":336,"type":20},"2026-06",{"name":338,"class":96},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":347,"minAge":348,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":52,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":40},"100608706","walking-for-hypothyroidism-trial-wht-100608706","NCT07205042","Walking for Hypothyroidism Trial (WHT)","A Randomized Controlled Trial of a 12-Week Walking Program on Metabolic and Psychophysiological Outcomes in Women With Hypothyroidism","WHT","Inclusion Criteria:\n\n* Female, aged 35-55 years\n* Primary hypothyroidism with documented prior TSH \\>4.5 mIU\u002FL\n* Stable levothyroxine dose for at least 6 months\n* Sedentary lifestyle (\\\u003C150 minutes of moderate-vigorous activity per week)\n* BMI between 20-35 kg\u002Fm²\n* Able to walk unaided\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating, or planning pregnancy during the study period\n* Use of beta-blockers, systemic corticosteroids, or medications significantly affecting heart rate, HRV, or metabolism\n* Uncontrolled hypertension, insulin-dependent diabetes, symptomatic cardiovascular disease, or orthopedic conditions limiting walking\n* Major psychiatric hospitalization in the past 12 months\n* Participation in another interventional trial within the past 30 days","FEMALE","35 Years","55 Years",{"count":351,"type":20},120,[142],"Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.",[25],[356,357,358,359,360],"Walking","Aerobic Exercise","Basal Metabolic Rate","Heart Rate Variability","Salivary Cortisol","2025-09-30",{"date":332,"type":34},{"date":364,"type":20},"2025-11-01",{"date":61,"type":20},{"name":367,"class":96},"University of Karachi",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":347,"minAge":348,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":52,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":40},"100574317","periodization-resistance-training-on-quality-of-life-in-females-with-hypothyroidism-100574317","NCT06757712","Periodization Resistance Training on Quality of Life in Females With Hypothyroidism","Nonlinear Versus Linear Periodized Resistance Training on Quality of Life in Females With Hypothyroidism","Inclusion Criteria:\n\n* Be controlled hypothyroidism (TSH level within 0.5 - 4.5 mU\u002FL)\n* Be ranged from 35 to 45 years\n* Female patients\n* Body Mass Index 30-34.9 kg\u002Fm2 .\n* triglyceride-glucose (TyG) index \\> 4.5\n\nExclusion Criteria:\n\n* history of pulmonary disease\n* Patients with uncontrolled coronary or cerebrovascular disease\n* Those who underwent musculoskeletal surgery within the previous year\n* Recent history of lower and upper limb fracture , hip and shoulder dislocation.\n* Cognitive impaired patients\n* Patients with history of epilepsy\n* Patients who participating in any other exercise program","45 Years",{"count":377,"type":20},75,[142],"This study will be conducted to compare between the effect of nonlinear and linear periodized training on quality of life in females with hypothyroidism.",[25],"2025-09-07",{"date":383,"type":34},"2025-09-12",{"date":385,"type":34},"2025-01-01",{"date":387,"type":20},"2025-10-15",{"name":389,"class":96},"Cairo University",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":52,"phases":399,"briefSummary":400,"conditions":401,"keywords":404,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":288},"100551075","patient-centered-dosage-of-levothyroxine-100551075","NCT06455371","Patient-centered Dosage of Levothyroxine","Patient-centered Decision Support Tool for Levothyroxine Dosage","Inclusion Criteria:\n\n* Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals\n\nExclusion Criteria:\n\n* Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy",{"count":398,"type":20},240,[142],"Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.",[25,402,403],"Thyroid Cancer","Thyroid",[405,406,407,408],"Decision support tool","Patient-centered dosage","thyroidectomy","levothyroxine","2025-09-03",{"date":411,"type":34},"2025-09-10",{"date":413,"type":34},"2024-12-20",{"date":63,"type":20},{"name":416,"class":96},"University Hospital of North Norway",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":424,"targetDuration":4,"studyType":52,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":40},"100360751","a-randomized-controlled-trial-of-thyroid-hormone-supplementation-in-hemodialysis-patients-100360751","NCT03977207","A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients","THYROID-HD","Inclusion Criteria:\n\n* Age 18-75 years old\n* Received hemodialysis at least four weeks\n* Have two consecutive thyrotropin (TSH) levels \\>3.0-10.0mIU\u002FL during the screening period\n* Have normal free thyroxine (FT4) levels\n* Have ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active treatment with thyroid hormone supplementation or anti-thyroid medications\n* Active receipt of dialysis\n* Prior kidney transplantation\n* Life expectancy less than six months\n* Active malignancy or prior thyroid malignancy\n* Active pregnancy or planning a pregnancy\n* Active coronary ischemia or atrial fibrillation (evaluated by EKG)\n* Active congestive heart failure exacerbation\n* Osteoporosis\n* Weight in excess of 450 lbs.\n* Hyperthyroidism as determined by TSH \\\u003C0.5mIU\u002FL during the screening period, anti-thyroid medication use, or hyperthyroidism diagnosis",{"count":425,"type":20},336,[142],"Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication in chronic kidney disease patients, and prior evidence shows that higher TSH levels, even within the normal laboratory range, are strongly associated with impaired quality of life and cardiovascular disease in this population. Levothyroxine is one of the most frequently prescribed medications in chronic kidney disease, yet its efficacy and safety in these patients have not been well-studied. Hence, this study will investigate 1) whether levothyroxine improves patient-centered (e.g., health-related quality of life, physical performance, strength) and 2) cardiovascular (e.g., coronary artery calcification, endothelial function, systolic function) outcomes in dialysis patients, and 3) if thyroid hormone replacement exerts classic metabolic effects (i.e., changes in body fat and resting energy expenditure) in this population.",[429,25,430],"Thyroid; Functional Disturbance","Hemodialysis","2025-08-30",{"date":433,"type":34},"2025-09-08",{"date":435,"type":34},"2020-07-20",{"date":437,"type":20},"2025-11-30",{"name":439,"class":96},"University of California, Irvine",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":448,"minAge":449,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":40},"100483908","thyroid-function-and-structure-in-klinefelter-syndrome-100483908","NCT05581147","Thyroid Function and Structure in Klinefelter Syndrome","Thyroid Function and Structure in Klinefelter Syndrome (THINKS)","THINKS","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of classic, non-mosaic 47,XXY Klinefelter syndrome based on a peripheral blood 97 karyotype analysis;\n* Availability of thyroid function test results (TSH, fT3, and fT4) and\u002For thyroid US imaging;\n* Availability of concurrent clinical data.\n\nExclusion Criteria:\n\n* Presence of other known genetic conditions or chromosomal abnormalities;\n* Use of levothyroxine or other drugs that are either active on the hypothalamic-pituitary-thyroid (HPT) axis or that may interfere with thyroid function tests;\n* History of previous surgery or radiotherapy on the thyroid or pituitary glands;\n* Current or previous T therapy (for the pre-pubertal and pubertal groups).","MALE","1 Year","80 Years",{"count":452,"type":20},600,"This is a longitudinal retrospective study for the evaluation of thyroid function and structure in patients with Klinefelter syndrome compared to healthy controls and patients affected by chronic lymphocytic thyroiditis.",[455,456,25],"Klinefelter Syndrome","Thyroiditis, Autoimmune",[458,25,459,460,461,462],"Klinefelter syndrome","Thyroiditis","Puberty","Prepuberty","Testosterone","2025-03-25",{"date":465,"type":34},"2025-03-30",{"date":467,"type":34},"2007-05-11",{"date":469,"type":20},"2026-12-01",{"name":471,"class":96},"University of Roma La Sapienza",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":478,"targetDuration":480,"studyType":21,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":40},"100576012","evaluation-of-different-diagnostic-therapeutic-strategies-in-patients-with-thyroid-pathology-100576012","NCT06779747","Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology","Inclusion Criteria:\n\n* Age older than 18 years at the time of diagnosis;\n* Patients with thyroid pathology (hypothyroidism, hyperthyroidism\u002Fthyrotoxicosis, benign thyroid nodule, and thyroid carcinoma) in whom the diagnosis was made in our Center or another Center from 01\u002F01\u002F1995 until the approval of this study (retrospective phase) or from the time of approval of this study to the next 10 years (prospective phase);\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Follow up lasting less than 3 months;\n* Incomplete or missing clinical data that may affect the correct assessment of the patient.",{"count":479,"type":20},5850,"20 Years","Observational single-center prospective and retrospective, nonpharmacological, spontaneous cohort study.",[25,483,484,485],"Hyperthyroidism\u002FThyrotoxicosis","Thyroid Nodule (Benign)","Thyroid Carcinoma","2025-01-13",{"date":488,"type":34},"2025-01-17",{"date":490,"type":34},"2021-12-30",{"date":492,"type":20},"2041-12-30",{"name":494,"class":96},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":15,"minAge":501,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":52,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":40},"100426357","hypothyroidism-after-the-tavi-procedure-in-elderly-patients-100426357","NCT04831957","Hypothyroidism After the TAVI Procedure in Elderly Patients","Inclusion Criteria:\n\n* Provision of signed and dated, written Informed Consent prior to any study specific proce-dures\n* Patient: males and females must be ≥ 70 years old\n* Patients who will undergo a TAVI procedure\n\nExclusion Criteria:\n\n* \\- No obtained signed, dated and written Informed Consent.\n* Known thyroid dysfunction (for example: Basedow, Hashimoto,...)\n* Patients receiving any of the following: Lithium, Strumazol or a recent treatment of radio-Iode","70 Years",{"count":5,"type":20},[142],"Aortic stenosis is highly prevalent in advancing age. The prognosis of this disease has dramatically changed with the surgical replacement of the aortic valve and the trans catheter aortic valve re-placement (TAVI). The TAVI procedure is also successful in octogenarians and frail patients. However, the evaluation before the TAVI procedure requires a high dosage of iodinated contrast agent with, consequently, an increased risk for thyroid dysfunction. The primary endpoint of this study is to assess, prospectively, the incidence and the predictive factors (underlying thyroid disease, medication, food preservative, topical antiseptics) of hypothyroidism after a TAVI procedure. The secondary endpoint is the influence of the occurrence of hypothyroidism after the TAVI procedure on the geriatric assessment.",[25,506],"TAVI",[25,506],"2024-12-04",{"date":510,"type":34},"2024-12-09",{"date":512,"type":34},"2021-07-26",{"date":514,"type":20},"2050-12-31",{"name":516,"class":96},"Universitair Ziekenhuis Brussel",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":525,"targetDuration":527,"studyType":21,"phases":4,"briefSummary":528,"conditions":529,"keywords":537,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":40},"100559587","register-for-patients-with-thyroid-hormone-resistance-100559587","NCT06566066","Register for Patients With Thyroid Hormone Resistance.","Deep Geno- and Phenotyping of Patients With Thyroid Hormone Resistance, a Register Study.","DEEPTYPE","Inclusion Criteria:\n\n* Presence of a coding or non-coding mutation in SLC16A2\n* Presence of a coding or non-coding mutation in THRA\n* Abnormal fT3\u002FfT4 ratio in the serum\n* Written informed consent of the caregivers for participation in the register study\n\nExclusion Criteria:\n\n* Withdrawal of consent\n* Correction\u002Fchange of the molecular diagnosis",{"count":526,"type":20},200,"5 Years","Thyroid hormones (TH) play a pivotal role in the development and function of the mammalian brain. Patients with impaired thyroid hormone transport into the brain tissue or in the case of defective local thyroid hormone receptor (collectively referred to as thyroid hormone resistance) subsequently experience psychomotor disabilities.\n\nThe \"DEEPTYPE\" registry has been established with the objective of intensifying the genotyping and, in particular, the neurological phenotyping of patients exhibiting deficiencies in either the thyroid hormone transporter (MCT8) or the thyroid hormone receptor alpha (THRα). The objective of this registry-based study is to enhance the diagnostic yield for MCT8 and THRα deficiencies by employing the serum fT3\u002FfT4 ratio as a more sophisticated screening parameter. Furthermore, the investigators will study the genomic regulation of both genes and attempt to identify further coding and non-coding mutations that result in TH resistance. The patient registry \"DEEPTYPE\" will document the retrospective and prospective clinical data of identified children in a comprehensive manner. This will enable the identification of three key groups: (i) patients with non-coding mutations, (ii) patients with milder phenotypes presenting only with a subset of symptoms seen in both \"classic\" conditions, and (iii) patients who are ready for clinical trials.",[25,530,531,532,533,534,535,536],"Global Developmental Delay","Intellectual Disability","Dystonia","Muscle Hypotonia","Seizures","Allan-Herndon-Dudley Syndrome","Microcephalus",[538,539,540,541,542,543],"Thyroid hormone","Thyroid hormone resistance","MCT8","SLC16A2","THRA deficiency","Myelination","2024-08-20",{"date":546,"type":34},"2024-08-22",{"date":548,"type":34},"2021-07-01",{"date":550,"type":20},"2029-07-31",{"name":552,"class":96},"Charite University, Berlin, Germany"]